CLASSIC HODGKIN LYMPHOMA
Clinical trials for CLASSIC HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSIC HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSIC HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy combo aims to stop hodgkin lymphoma return after transplant
Disease control OngoingThis phase 2 trial is testing whether two immunotherapy drugs, nivolumab and brentuximab vedotin, can help prevent Hodgkin lymphoma from coming back after a stem cell transplant. The study includes 62 patients with high-risk classical Hodgkin lymphoma that has returned or not res…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Engineered immune cells take aim at tough lymphomas in first human test
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
Can an old drug make immunotherapy work again for tough lymphomas?
Disease control OngoingThis early-phase study tests whether adding an oral drug called CC-486 (azacitidine) to the immunotherapy nivolumab can help people with Hodgkin lymphoma whose cancer no longer responds to PD-1 blockers. About 33 participants will receive the combination to find the safest dose a…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
Smart scans guide tailored therapy for hodgkin lymphoma patients
Disease control OngoingThis study tests a personalized approach for people with early-stage Hodgkin lymphoma. Doctors use PET scans to decide if standard chemotherapy alone is enough or if adding immunotherapy drugs can improve results. The goal is to boost survival while limiting unnecessary treatment…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New hope for seniors with hodgkin lymphoma: Chemo-Free combo shows promise
Disease control OngoingThis study tests a combination of two drugs, nivolumab and brentuximab vedotin, in people aged 60 or older (or younger people who cannot take standard chemotherapy) with untreated Hodgkin lymphoma. The goal is to see how well this drug pair works in shrinking or eliminating the c…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Immunotherapy showdown: new hope for advanced hodgkin lymphoma patients
Disease control OngoingThis large phase 3 study compares two immunotherapy drugs (nivolumab or brentuximab vedotin) given with standard chemotherapy for people aged 12 and older with newly diagnosed, advanced-stage classical Hodgkin lymphoma. The goal is to see which combination better delays the cance…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
New combo therapy aims to beat High-Risk hodgkin lymphoma in kids
Disease control OngoingThis study tests whether adding brentuximab vedotin (a drug that delivers cancer-killing substances directly to lymphoma cells) to standard chemotherapy works better than chemo alone for children and young adults with high-risk Hodgkin lymphoma. About 600 participants with stage …
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC